Genmab Announces Data to be Presented at 2019 ASCO Annual Meeting
April 17, 2019 10:52 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, April 17, 2019 14 industry sponsored abstracts regarding Genmab programs selected for presentation at ASCO Annual Meeting Genmab A/S (Nasdaq Copenhagen: GEN)...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019
April 16, 2019 06:46 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April...
Genmab Announces Submission of Supplemental New Drug Application in Japan for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
April 05, 2019 01:59 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, April 5, 2019 Supplemental new drug application (sNDA) submitted in Japan for daratumumab in combination with lenalidomide and dexamethasone as treatment for...
Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma
April 03, 2019 07:33 ET
|
Genmab A/S
Company Announcement Phase III study to examine daratumumab plus lenalidomide as maintenance treatment in patients with newly diagnosed multiple myelomaStudy utilizes the subcutaneous formulation of...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
April 02, 2019 12:21 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; April 2, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 146,961 shares as a consequence of the exercise of employee warrants. ...
Genmab to Present at the H.C. Wainwright & Co. Global Life Sciences Conference
April 02, 2019 08:58 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, April 2, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the H.C. Wainwright &...
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
March 29, 2019 13:57 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; March 29, 2019 – Following Genmab A/S’ (Nasdaq Copenhagen: GEN) Annual General Meeting held on March 29, 2019, the Company’s Board of Directors met to...
Passing of Genmab A/S’ Annual General Meeting
March 29, 2019 08:11 ET
|
Genmab A/S
Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2019, the Annual Report for 2018 was approvedDischarge was given to the Board of Directors and the Executive Management...
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
March 27, 2019 05:12 ET
|
Genmab A/S
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with...
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
March 26, 2019 09:20 ET
|
Genmab A/S
Company Announcement sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are...